Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: Faster-acting insulin aspart
Drug: insulin aspart

First Posted Date: 2014-05-06

Last Posted Date: 2017-01-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 33

Registration Number: NCT02131246

Locations: 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria

Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: semaglutide
Drug: insulin glargine

First Posted Date: 2014-05-01

Last Posted Date: 2019-06-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1089

Registration Number: NCT02128932

Locations: 🇬🇧
Novo Nordisk Investigational Site, Taunton, United Kingdom

A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba® (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec

First Posted Date: 2014-04-21

Last Posted Date: 2017-08-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1056

Registration Number: NCT02117622

Locations: 🇮🇳
Novo Nordisk Investigational Site, Thriruvananthapuram, India

A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec/liraglutide
Drug: insulin aspart

First Posted Date: 2014-04-01

Last Posted Date: 2017-01-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 31

Registration Number: NCT02100475

Locations: 🇪🇸
Novo Nordisk Investigational Site, Valencia, Spain

The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: placebo
Drug: liraglutide

First Posted Date: 2014-03-28

Last Posted Date: 2017-02-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 835

Registration Number: NCT02098395

Locations: 🇸🇪
Novo Nordisk Investigational Site, Örebro, Sweden

A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Phase 2

Withdrawn

Conditions: Inflammation
Rheumatoid Arthritis

Interventions: Drug: NNC0109-0012
Drug: Adalimumab
Drug: placebo

First Posted Date: 2014-03-27

Last Posted Date: 2014-08-15

Lead Sponsor: Novo Nordisk A/S

Registration Number: NCT02097264

Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: NNC0113-0987

First Posted Date: 2014-03-24

Last Posted Date: 2015-01-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 122

Registration Number: NCT02094521

A Trial Comparing the Pharmacokinetic Properties of Faster-acting Insulin Aspart (FIAsp) After Different Injection Regions and Routes of Administration in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: Faster-acting insulin aspart

First Posted Date: 2014-03-17

Last Posted Date: 2017-02-17

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 21

Registration Number: NCT02089451

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects

Phase 1

Withdrawn

Conditions: Congenital Bleeding Disorder
Haemophilia A
Haemophilia A With Inhibitors
Haemophilia B
Haemophilia B With Inhibitors
Healthy

Interventions: Drug: activated recombinant human factor VII
Drug: eptacog alfa (activated)

First Posted Date: 2014-03-12

Last Posted Date: 2014-03-26

Lead Sponsor: Novo Nordisk A/S

Registration Number: NCT02084810

Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo

Phase 1

Completed

Conditions: Diabetes
Obesity
Metabolism and Nutrition Disorder

Interventions: Drug: placebo
Drug: semaglutide

First Posted Date: 2014-03-06

Last Posted Date: 2017-12-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 30

Registration Number: NCT02079870

Locations: 🇬🇧
Novo Nordisk Investigational Site, Leeds, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy